Novel coronavirus infection: a new challenge for the management of thyroid disease

Abstract

CLC Number:

R593.2

XIANG Pingping, LIU Chao. Novel coronavirus infection: a new challenge for the management of thyroid disease[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 486-490.

References23

[24]	Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019[J]. BMJ, 2020, 368: m1091.
[25]	Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19[J]. Thyroid, 2021, 31(1): 8-11. doi:10.1089/thy.2020.0363 URL
[26]	Moore JB, June CH. Cytokine release syndrome in severe COVID-19[J]. Science, 2020, 368(6490): 473-474. doi:10.1126/science.abb8925pmid:32303591
[27]	Tang Y, Liu J, Zhang D, et al. Cytokine storm in COVID-19[J]. Front Immunol, 2020, 11: 1708. doi:10.3389/fimmu.2020.01708 URL
[28]	De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia[J]. Nat Commun, 2020, 11(1): 3434. doi:10.1038/s41467-020-17292-4pmid:32632085
[29]	Ruggeri RM, Giuffrida G, Campennì A. Autoimmune endocrine diseases[J]. Minerva Endocrinol, 2018, 43(3): 305-322. doi:10.23736/S0391-1977.17.02757-2pmid:28990742
[30]	Nanba T, Watanabe M, Inoue N, et al. Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease[J]. Thyroid, 2009, 19(5): 495-501. doi:10.1089/thy.2008.0423 URL
[31]	Shi Y, Wang H, Su Z, et al. Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto’s thyroiditis[J]. Scand J Immunol, 2010, 72(3): 250-255. doi:10.1111/j.1365-3083.2010.02425.xpmid:20696023
[32]	Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, et al. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis[J]. J Clin Endocrinol Metab, 2010, 95(2): 953-962. doi:10.1210/jc.2009-1719pmid:20016049
[33]	Li Q, Wang B, Mu K, et al. The pathogenesis of thyroid autoimmune diseases: new T lymphocytes-cytokines circuits beyond the Th1-Th2 paradigm[J]. J Cell Physiol, 2019, 234(3): 2204-2216. doi:10.1002/jcp.27180 URL
[34]	Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with COVID-19[J]. Eur J Endocrinol, 2020, 183(4): 381-387. doi:10.1530/EJE-20-0335 URL
[35]	Campi I, Bulgarelli I, Dubini A, et al. The spectrum of thyroid function tests during hospitalization for SARS COV-2 infection[J]. Eur J Endocrinol, 2021, 184(5): 699-709. doi:10.1530/EJE-20-1391pmid:33683214
[36]	Wang W, Zhang W, Zhang J, et al. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019(COVID-19)[J]. HLA, 2020, 96(2): 194-196. doi:10.1111/tan.13941 URL
[37]	Novelli A, Andreani M, Biancolella M, et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients[J]. HLA, 2020, 96(5): 610-614. doi:10.1111/tan.14047 URL
[38]	Ohsako N, Tamai H, Sudo T, et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing[J]. J Clin Endocrinol Metab, 1995, 80(12):3653-3656. doi:10.1210/jcem.80.12.8530615 URL
[39]	Grumet FC, Payne RO, Konishi J, et al. HL-A antigens as markers for disease susceptibility and autoimmunity in Graves’ disease[J]. J Clin Endocrinol Metab, 1974, 39(6): 1115-1119. doi:10.1210/jcem-39-6-1115 URL
[1]	World Health Organization. Coronavirus disease (COVID-2019) situation reports[EB/OL]. 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
[2]	Temgoua MN, Endomba FT, Nkeck JR, et al. Coronavirus disease 2019(COVID-19) as a multi-systemic disease and its impact in low- and middle-income countries (LMICs)[J]. SN Compr Clin Med, 2020, 2(9): 1377-1387. doi:10.1007/s42399-020-00417-7 URL
[40]	Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function[J]. Endocr Rev, 2003, 24(5): 694-717. doi:10.1210/er.2002-0030pmid:14570752
[41]	Lazartigues E, Qadir MMF, Mauvais-Jarvis F. Endocrine significance of SARS-CoV-2’s reliance on ACE2[J]. Endocrinology. 2020, 161(9): bqaa108. doi:10.1210/endocr/bqaa108 URL
[3]	Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored[J]. J Endocrinol Invest, 2020, 43(7): 1027-1031. doi:10.1007/s40618-020-01276-8pmid:32361826
[4]	Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis[J]. J Endocrinol Invest, 2021, 44(5): 1085-1090. doi:10.1007/s40618-020-01436-wpmid:33025553
[42]	van Gerwen M, Alsen M, Little C, et al. Outcomes of patients with hypothyroidism and COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11: 565. doi:10.3389/fendo.2020.00565 URL
[43]	Zhang Y, Lin F, Tu W, et al. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19[J]. Mol Cell Endocrinol, 2021, 521: 111097. doi:10.1016/j.mce.2020.111097 URL
[5]	Gorini F, Bianchi F, Iervasi G. COVID-19 and thyroid: progress and prospects[J]. Int J Environ Res Public Health, 2020, 17(18): 6630. doi:10.3390/ijerph17186630 URL
[6]	孙申, 卫兰, 张京, 等. 严重急性呼吸综合征患者甲状腺的病理学改变[J]. 中华医学杂志, 2005, 85(10): 667-670.
[44]	Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019(COVID-19) infection[J]. Diabetes Metab Syndr, 2020, 14(5):1429-1430. doi:S1871-4021(20)30292-7pmid:32755846
[45]	Weisberg E, Parent A, Yang PL, et al. Repurposing of kinase inhibitors for treatment of COVID-19[J]. Pharm Res, 2020, 37(9):167.
[7]	Bradley BT, Maioli H, Johnston R, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State[J]. Lancet, 2020, 396(10247): 320-332. doi:10.1016/S0140-6736(20)31305-2 URL
[8]	Barton LM, Duval EJ, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA[J]. Am J Clin Pathol, 2020, 153(6): 725-733. doi:10.1093/ajcp/aqaa062pmid:32275742
[46]	Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic[J]. JAMA, 2020, 324(13): 1292-1295.
[47]	Elston MS, Conaglen HM, Hughes C, et al. Duration of cortisol suppression following a single dose of dexamethasone in healthy volunteers: a randomised double-blind placebo-controlled trial[J]. Anaesth Intensive Care, 2013, 41(5): 596-601.
[9]	姚小红, 李廷源, 何志承, 等. 新型冠状病毒肺炎(COVID-19)三例遗体多部位穿刺组织病理学研究[J]. 中华病理学杂志, 2020, 49(5): 411-417.
[10]	Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after SARS-COV-2 infection[J]. J Clin Endocrinol Metab, 2020, 105(7): dgaa276.
[48]	Alkemade A, Unmehopa UA, Wiersinga WM, et al. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus[J]. J Clin Endocrinol Metab, 2005, 90(1): 323-327.
[49]	Schatz DL, Sheppard RH, Steiner G, et al. Influence of heparin on serum free thyroxine[J]. J Clin Endocrinol Metab, 1969, 29(8): 1015-1022.
[11]	Inaba H, Aizawa T. Coronavirus disease 2019 and the thyroid[J]. Front Endocrinol (Lausanne), 2021, 12: 708333. doi:10.3389/fendo.2021.708333 URL
[12]	Mattar SAM, Koh SJQ, Rama Chandran S, et al. Sub-acute thyroiditis associated with COVID-19[J]. BMJ Case Rep, 2020, 13(8): e237336. doi:10.1136/bcr-2020-237336 URL
[50]	Mendel CM, Frost PH, Cavalieri RR. Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin[J]. J Clin Endocrinol Metab, 1986, 63(6): 1394-1399.
[51]	Mendel CM, Frost PH, Kunitake ST, et al. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma[J]. J Clin Endocrinol Metab, 1987, 65(6):1259-1264.
[13]	Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis[J]. Lancet Diabetes Endocrinol, 2020, 8(9): 739-741. doi:10.1016/S2213-8587(20)30266-7 URL
[14]	Ruggeri RM, Campennì A, Siracusa M, et al. Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic[J]. Hormones (Athens), 2021, 20(1): 219-221. doi:10.1007/s42000-020-00230-w URL
[15]	Mizuno S, Inaba H, Kobayashi KI, et al. A case of postpartum thyroiditis following SARS-CoV-2 infection[J]. Endocr J, 2021, 68(3): 371-374. doi:10.1507/endocrj.EJ20-0553pmid:33177251
[16]	Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19[J]. J Endocrinol Invest, 2020, 43(10):1527-1528. doi:10.1007/s40618-020-01366-7pmid:32686042
[17]	Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves’ hyperthyroidism?[J]. J Endocrinol Invest, 2021, 44(2): 387-388. doi:10.1007/s40618-020-01440-0pmid:33025554
[18]	Pastor S, Molina Á Sr, De Celis E. Thyrotoxic crisis and COVID-19 infection[J]. Cureus, 2020, 12(11):e11305.
[52]	Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination[J]. Thyroid, 2021, 31(9): 1436-1439.
[53]	Iremli BG, Şendur SN, Ünlütürk U. Three cases of subacute thyroiditis following SARS-CoV-2 vaccine[J]. J Clin Endocrinol Metab, 2021, 106(9): 2600-2605.
[19]	Tee LY, Harjanto S, Rosario BH. COVID-19 complicated by Hashimoto’s thyroiditis[J]. Singapore Med J, 2021, 62(5):265. doi:10.11622/smedj.2020106 URL
[20]	Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(2): e926-e935. doi:10.1210/clinem/dgaa813pmid:33141191
[21]	Boelaert K, Visser WE, Taylor PN, et al. Endocrinology in the time of COVID-19[J]. Eur J Endocrinol, 2020, 183(1): G33-G39. doi:10.1530/EJE-20-0445 URL
[22]	Zou R, Wu C, Zhang S, et al. Euthyroid sick syndrome in patients with COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11: 566439. doi:10.3389/fendo.2020.566439 URL
[54]	Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens[J]. Front Immunol, 2020, 11:617089.
[23]	Gao W, Guo W, Guo Y, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19[J]. J Endocrinol Invest, 2021, 44(5):1031-1040. doi:10.1007/s40618-020-01460-wpmid:33140379

Novel coronavirus infection: a new challenge for the management of thyroid disease

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References23

Related Articles10

Recommended Articles

Metrics

Comments

[1]	ZHOU Yi, CHEN Ying, CHEN Erzhen.Research progress of thyroid hormone on organ function maintenance in sepsis[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 408-412.
[2]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(04): 339-343.
[3]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 262-266.
[4]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 258-261.
[5]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 202-207.
[6]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 267-272.
[7]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 181-185.
[8]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 186-189.
[9]	.[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 190-194.
[10]	.[J]. Journal of Internal Medicine Concepts & Practice, 2021, 16(04): 270-271.